NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S....
Fangzhou Designated as a 2024 National High-Tech Enterprise Amid Record Growth
BEIJING, April 3, 2025 /PRNewswire/ -- Beijing Fangyixing Information Technology Co., Ltd. ("Fangyixing"), a subsidiary of China's leading Internet healthcare solutions provider Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), has been...